Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPAMI: Rapamycin in Inclusion Body Myositis
NCT02481453Phase 3Completed
- Sponsor
- Inserm
- Start
- Jul 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in inclusion body myositis (IBM) comparing Rapamycin with Placebo (2 arms). Primary endpoint: Stabilization of quadriceps strength measured by myometry at 52 weeks. Started Jul 2015; status: completed.
02
Drugs
sirolimus
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on NCT02481453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02481453.